ISSN: 1359-6446

Journal Home

Journal Guideline

Drug Discovery Today Q1 Unclaimed

Elsevier Ltd. Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Discovery Today is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 167. It has a price of 2395 €. It has an SJR impact factor of 1,896 and it has a best quartile of Q1. It is published in English.

Drug Discovery Today focuses its scope in these topics and keywords: drug, library, cancer, discovery, clinical, development, drugs, data, crowd, class, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Drug Discovery (Q1) Pharmacology (Q1)

Price

2395 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

1,896

SJR Impact factor

167

H Index

263

Total Docs (Last Year)

620

Total Docs (3 years)

18902

Total Refs

4384

Total Cites (3 years)

580

Citable Docs (3 years)

7,65

Cites/Doc (2 years)

71,87

Ref/Doc

Other journals with similar parameters

Nature Reviews Drug Discovery Q1
Perspectives in Medicinal Chemistry Q1
Molecular Therapy Q1
Natural Product Reports Q1
Cell Chemical Biology Q1

Aims and Scope

Best articles

Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery

Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance

Antisense Drug Technology: Principles, Strategies, and Applications

Beating superbugs with the Gulliver effect

Bilosomes: the answer to oral vaccine delivery?

Can you stand the heat of today's drug discovery?

Cell signaling: signal transduction and gene transcription

Challengeability of biotechnology patents in the light of Biogen v. Medeva

Chemokines and their receptors

Chiral Europe '95

Chiroscience/BMS MMP inhibitor progress

CombiChem deal

SHOW MORE ARTICLES

Combinatorial approaches to chemistry and biology

Combinatorial chemistry

Combining drug-disease and economic modelling to inform drug development decisions

Comparison of some major information resources in pharmaceutical competitor tracking

Corporate intelligence in biotechnology

Could insulin protect against atherosclerosis?

Design and discovery of neuropeptide Y1 receptor antagonists

Diversa and diversity

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.